Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects

Dissimilar PTH, Gastrin, and Ionized Calcium Response to Oral Peptones in Normocalcemic Primary Hyperparathyroidism, Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01042626

Enrollment

Registered

2010-01-05

Start date

2004-07-31

Completion date

2005-01-31

Last updated

2010-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercalcemia, Hyperparathyroidism

Keywords

Receptors, Calcium sensing, Parathyroid Hormone

Brief summary

The purpose of this study is to assess if subjects with hyperparathyroidism with normal serum calcium levels have different responses in the calcium regulating hormonal handling compared to a) patients with primary hyperparathyroidism and high serum calcium levels; b) healthy subjects. The differences will be evaluated with oral peptones load and subsequent blood samples collected every 15 minutes for two hours. Ionized calcium, phosphate, gastrin and PTH levels will be evaluated.

Interventions

OTHEROral peptones load

Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline

Study design

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

1. normocalcemic hyperparathyroidism * presence of high serum levels of intact PTH * serum ionized calcium levels in the high normality range 2. hypercalcemic hyperparathyroidism * presence of high serum levels of intact PTH * high serum ionized calcium levels

Exclusion criteria

1. potential causes of secondary hyperparathyroidism like renal insufficiency, liver disease, malabsorption, hypercalciuria, Paget's disease, thiazide diuretic or lithium use. 2. bone disease of any origin

Design outcomes

Primary

Measure	Time frame
PTH levels variations	2 hours
Ionized serum calcium variations	2 hours
Serum phosphate variations	2 hours
Serum gastrin variations	2 hours

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026